A potent inhibitor of mammalian histone deacetylases (HDACs) (IC₅₀ = 15.7 nM). A novel antitumor agent; oxamflatin modifies epigenetic status and gene expression, increases blastocyst quality, and subsequently enhances the nuclear reprogramming and developmental potential of SCNT (somatic cell nuclear transfer) embryos.